Interaction Checker

Interações de Gefitinibe

Gefitinibe (Iressa) tem 108 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 8; moderadas: 100; leves: 0; casos em que uma bula relata não haver interação significativa: 0). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.

Interações segundo a bula

Interações graves (8)

  • Dexlansoprazolinibidor da bomba de prótonsGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (bula de Gefitinibe, Interações medicamentosas)

  • Esomeprazolinibidor da bomba de prótonsGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (bula de Gefitinibe, Interações medicamentosas)

  • Lansoprazolinibidor da bomba de prótonsGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (bula de Gefitinibe, Interações medicamentosas)

  • Naproxeno + esomeprazolAINEGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (bula de Gefitinibe, Interações medicamentosas)

  • Omeprazolinibidor da bomba de prótonsGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (bula de Gefitinibe, Interações medicamentosas)

  • Omeprazol + bicarbonato de sódioinibidor da bomba de prótonsGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (bula de Gefitinibe, Interações medicamentosas)

  • Pantoprazolinibidor da bomba de prótonsGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (bula de Gefitinibe, Interações medicamentosas)

  • Rabeprazolinibidor da bomba de prótonsGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (bula de Gefitinibe, Interações medicamentosas)

Interações moderadas (100)

  • AmiodaronaantiarrítmicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Amitriptilinaantidepressivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • Amoxapinaantidepressivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • Antiácidos (Tums, Maalox, Mylanta)Produtos de venda livreModerada

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (bula de Gefitinibe, Interações medicamentosas)

  • Aprepitantoinibidor da CYP3A4Moderada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Armodafinilaestimulante do SNCModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • AtazanavirantirretroviralModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Bicarbonato de sódioantiácidoModerada

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (bula de Gefitinibe, Interações medicamentosas)

  • Bosentanaindutor da CYP3A4Moderada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • BupropionaantidepressivoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • CarbamazepinaanticonvulsivanteModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • CenobamatoanticonvulsivanteModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Cetoconazolantifúngico azólicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • CiclosporinaimunossupressorModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Cimetidinabloqueador H2Moderada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • CitalopramISRSModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • Claritromicinaantibiótico macrolídeoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • ClobazambenzodiazepínicoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Clomipraminaantidepressivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • DarunavirantirretroviralModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Darunavir + cobicistateantirretroviralModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Deferasiroxsuplemento de ferroModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Desipraminaantidepressivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • DesvenlafaxinaIRSNModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • DexametasonacorticosteroideModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Diltiazembloqueador dos canais de cálcioModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Doxepinaantidepressivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • DronedaronaantiarrítmicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • DuloxetinaIRSNModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • EfavirenzantirretroviralModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Efavirenz + lamivudina + tenofovirantirretroviralModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Elvitegravir + cobicistate + entricitabina + tenofovirantirretroviralModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Eritromicinaantibiótico macrolídeoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • EscitalopramISRSModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • EslicarbazepinaanticonvulsivanteModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • EtravirinaantirretroviralModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • EverolimoimunossupressorModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Famotidinabloqueador H2Moderada

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (bula de Gefitinibe, Interações medicamentosas)

  • Fenelzinainibidor da MAOModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • FenitoínaanticonvulsivanteModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • FenobarbitalbarbitúricoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Fentermina + topiramatoestimulante do SNCModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Fluconazolantifúngico azólicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • FluoxetinaISRSModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • FluvoxaminaISRSModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • FosamprenavirantirretroviralModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Fosaprepitantoinibidor da CYP3A4Moderada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • FosfenitoínaanticonvulsivanteModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • GriseofulvinaantifúngicoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Ibuprofeno + famotidinaAINEModerada

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (bula de Gefitinibe, Interações medicamentosas)

  • Imatinibeinibidor da CYP3A4Moderada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Imipraminaantidepressivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • IsoniazidaantibióticoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Itraconazolantifúngico azólicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Ivacaftorinibidor da CYP3A4Moderada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • LenacapavirantirretroviralModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • LevomilnacipranaIRSNModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • Lopinavir + ritonavirantirretroviralModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Lorlatinibeindutor da CYP3A4Moderada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Mifepristonainibidor da CYP3A4Moderada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Mirabegronaagonista beta-adrenérgicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • MirtazapinaantidepressivoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • Mitapivateindutor da CYP3A4Moderada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Mitotanoindutor da CYP3A4Moderada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Modafinilaestimulante do SNCModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Nafcilinaantibiótico da classe das penicilinasModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Naltrexona + bupropionaantagonista opioideModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • NefazodonaantidepressivoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • NevirapinaantirretroviralModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Nirmatrelvir + ritonavirantiviralModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Nizatidinabloqueador H2Moderada

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (bula de Gefitinibe, Interações medicamentosas)

  • Nortriptilinaantidepressivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • Olanzapina + fluoxetinaantipsicóticoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • OxcarbazepinaanticonvulsivanteModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Palbociclibeinibidor da CYP3A4Moderada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • ParoxetinaISRSModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • PerampanelanticonvulsivanteModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Posaconazolantifúngico azólicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • PrimidonaanticonvulsivanteModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Protriptilinaantidepressivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • Ranitidinabloqueador H2Moderada

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (bula de Gefitinibe, Interações medicamentosas)

  • Ranolazinamedicamento que prolonga o intervalo QTModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • RifabutinaantibióticoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • RifampicinaantibióticoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • RifapentinaantibióticoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • RitonavirantirretroviralModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • SertralinaISRSModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • Suvorexantosedativo-hipnóticoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • Suzetriginaindutor da CYP3A4Moderada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Ticagrelorantiagregante plaquetárioModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • TopiramatoanticonvulsivanteModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

  • Tranilciprominainibidor da MAOModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • TrazodonaantidepressivoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • Trimipraminaantidepressivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • VarfarinaanticoagulanteModerada

    • Hemorrhage in patients taking warfarin: Monitor changes in prothrombin time or INR. (bula de Gefitinibe, Interações medicamentosas)

  • VenlafaxinaIRSNModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • Verapamilbloqueador dos canais de cálcioModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • VilazodonaISRSModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

  • Voriconazolantifúngico azólicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (bula de Gefitinibe, Interações medicamentosas)

  • VortioxetinaantidepressivoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

Verifique Gefitinibe com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.

Abrir no verificador

Não é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.